Biohaven reports confirmed BHV-1530 responses in two FGFR3 cancers
Biohaven said its experimental BHV-1530 showed confirmed responses in patients with FGFR3-altered urothelial and head and neck cancers in Phase 1 data presented at ENA 2026. The findings create an early clinical readout for the company’s FGFR3-directed antibody-drug conjugate and its proprietary TopoIx payload.
PR NEWSWIRE / FILEThe story
Biohaven presented Phase 1 results for BHV-1530 in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The company described the responses as deep and durable in patients with FGFR3-altered urothelial cancer and head and neck squamous cell carcinoma, with confirmed responses reported across the studied cancers.
The presentation places BHV-1530 at an early clinical stage: the program is a novel FGFR3-directed antibody-drug conjugate built around Biohaven’s proprietary TopoIx payload. The current update concerns clinical activity in Phase 1 rather than a later-stage efficacy result.
The findings touch Biohaven through the development of BHV-1530 and its potential use in tumors carrying FGFR3 alterations, including urothelial and head and neck cancers. The mechanism connects the antibody component, the FGFR3 target and the TopoIx payload in a single investigational treatment.
The evidence remains an early clinical readout, and the reported responses do not by themselves establish approval, durability across a broader population or comparative benefit against existing treatments. The next material checkpoints are further clinical follow-up and any subsequent study updates that clarify the response rate, duration and safety profile.
Our read · Thu, Nov 19
BHVN reported confirmed responses for its BHV-1530 antibody-drug conjugate in FGFR3-altered urothelial and head and neck cancers.
Why. The readout gives Biohaven an early clinical validation point for a targeted oncology program, but the trade remains dependent on whether the responses persist and expand beyond the Phase 1 setting. No dated follow-up event is established here, so the evidence supports monitoring the next efficacy and safety update rather than a directional call.
Both cases
What could change this view: The response signal may not translate into durable benefit or a sufficiently broad efficacy and safety profile in later-stage development.
Who reported it · 1
Keep reading
Latest on the Wire
Greer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultAnthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeContinue on the Wire →Latest on the Wire
Beijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesChina seeks protections to restart US private-equity investmentsAMD shares fall 11% after Hunterbrook warns over China linksContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by PR Newswire as Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →